GDC-0326 is primarily investigated for its potential in cancer therapy, particularly as a targeted treatment for certain types of tumors. It functions as a selective inhibitor of specific signaling pathways that are often dysregulated in cancer cells, such as the PI3K/AKT/mTOR pathway. By blocking these pathways, it aims to inhibit tumor growth and proliferation. Its application is most relevant in preclinical and clinical studies focused on solid tumors and hematologic malignancies, where it shows promise in enhancing the efficacy of existing treatments or as a standalone therapy. Research is ongoing to determine its safety, optimal dosing, and potential combination with other anticancer agents.